摘要
脂蛋白磷脂酶a2（Lp—PLA2）也称血浆血小板激活因子乙酰水解酶，Lp—PLA2主要是由巨噬细胞产生分泌，血浆中大约70％的Lp—PLA2与低密度脂蛋白（LDL）结合。Lp—PLA2作为一个近期新发现的血管炎性反应物质可能直接参与动脉粥样硬化斑块的形成、稳定性丧失及破裂，最终导致急性心脑血管危险事件的发生。Lp-PLA2与超敏C－反应蛋白（hs—CRP）相比是一个更具有特异性的动脉粥样硬化的标志物，同时遗传、环境、他汀类药物及选择性Lp—PLA2抑制剂等对Lp—PLA2的水平也有着很大的影响，相信随着Lp—PLA2的不断研究发展，在预防、治疗动脉粥样硬化疾病中将提供一种新的更有效地治疗方法，可以准确、及时地反映血管炎症的严重程度，预防急性心脑血管危险事件的发生。
Lipoprotein phospholipase A2 （Lp-PLA2）, also known as the plasma platelet activating factor acetyl hydrolase, is mainly produced and secreted by macrophages. About 70% of the Lp- PLA2 in plasma combined with low density lipoprotein （LDL）, Lp-PLA2 as a recent new finding of vascu- lar inflammatory reaction substance may be directly participate in the formation of atherosclerotic plaque, the loss of stability and rupture, eventually leading to acute cardiovascular risk events occur. Compared with hypersensitive c-reactive protein （hs-CRP）, Lp-PLA2 is a more specific marker of ath- erosclerosis. Genetic factors, environmental factors, statins and selective Lp-PLA2 inhibitors also have great influences on the lipoprotein level of phospholipase A2-（Lp-PLA2）. We believe that by the future investigations of Lp-PLA2, it will provide a new and more effective treatment for the prevention and treatment of atherosclerosis disease; Lp-PLA2 can accurately and timely reflect the severity of the vascular inflammation, prevent the occurrence of acute cardio-eerebrovascular events.
出处
《中国急救医学》
CAS
CSCD
北大核心
2016年第5期476-480,共5页
Chinese Journal of Critical Care Medicine
